Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data

被引:54
|
作者
Xu, Chuanhui [1 ]
Yi, Zixi [2 ]
Cai, Ruyi [2 ]
Chen, Ru [3 ]
Thong, Bernard Yu-Hor [1 ]
Mu, Rong [2 ]
机构
[1] Tan Tock Seng Hosp, Dept Rheumatol Allergy & Immunol, Singapore 308433, Singapore
[2] Peking Univ Third Hosp, Dept Rheumatol & Immunol, 49 Huayuan North Rd, Beijing 100191, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
关键词
Rheumatic diseases; COVID-19; Outcomes; SARS-CoV-2; CORTICOSTEROIDS; ARTHRITIS; COHORT; SERIES;
D O I
10.1016/j.autrev.2021.102778
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: The impact of rheumatic diseases on COVID-19 infection remains poorly investigated. Here we performed a systematic review and meta-analysis to evaluate the outcomes of COVID-19 in patients with rheumatic diseases. Methods: We systematically searched PubMed, Embase, Cochrane Library, Scopus and preprint database up to 29th August 2020, for publications with confirmed COVID-19 infection in patients with rheumatic diseases. The primary outcomes were the rates of hospitalization, oxygen support, intensive care unit (ICU) admission and death. A meta-analysis of effect sizes using the random-effects models was performed, and meta-regression analyses were performed to explore heterogeneity. The data from the COVID-19 Global Rheumatology Alliance physician registry (the COVID-19 GRA) was used as a reference. Results: A total of 31 articles involving 1138 patients were included in this systematic review and meta-analysis. The publications were from Europe, Asia and North America, but none from other continents. The overall rates of hospitalization, oxygen support, ICU admission and fatality among COVID-19 infected patients with rheumatic diseases were 0.58 (95% confidence interval (CI) 0.48-0.67), 0.33 (95% CI 0.21-0.47), 0.09 (95% CI 0.05-0.15) and 0.07 (95% CI 0.03-0.11), respectively. The rate of oxygen support in Europe (0.48, 95% CI 0.4-0.57) was higher than that in other continents. Among all hospitalized patients, the rates of oxygen support, ICU admission and fatality were 0.61 (95% CI 0.48-0.73), 0.13 (95% CI 0.07-0.21) and 0.13 (95% CI 0.09-0.18), respectively. The fatality rate was highest in Europe (0.19, 95% CI 0.15-0.24). The fatality rate was higher both in this meta-analysis and the COVID-19 GRA (7.0% and 6.7%, respectively) than that (3.4%) in WHO database, although the age, gender and comorbidity were not matched. Conclusion: Patients with rheumatic diseases remain vulnerable with substantial rates of severe outcomes and a geographic variation. More studies were urgently needed to elucidate the risk factors of severe outcomes in this population.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] COVID-19 Infection and Outcomes in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis
    Sood, Akhil
    Gandhi, Ronak
    Murthy, Vijaya
    Gonzalez, Emilio
    Raji, Mukaila
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 211 - 212
  • [2] Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis
    Wang, Qingxiu
    Liu, Jianbo
    Shao, Runxia
    Han, Xiaopeng
    Su, Chenhao
    Lu, Wenjia
    RHEUMATOLOGY INTERNATIONAL, 2021, 41 (05) : 851 - 861
  • [3] Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis
    Qingxiu Wang
    Jianbo Liu
    Runxia Shao
    Xiaopeng Han
    Chenhao Su
    Wenjia Lu
    Rheumatology International, 2021, 41 : 851 - 861
  • [4] Prevalence and risk of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis
    Wang, Feier
    Ma, Yubo
    Xu, Shanshan
    Liu, Huanhuan
    Chen, Yuting
    Yang, Hui
    Shao, Ming
    Xu, Wei
    Kong, Jiangping
    Chen, Liwen
    Xu, Shengqian
    Shuai, Zongwen
    Pan, Faming
    CLINICAL RHEUMATOLOGY, 2022, 41 (07) : 2213 - 2223
  • [5] COVID-19 susceptibility and clinical outcomes in autoimmune inflammatory rheumatic diseases (AIRDs): a systematic review and meta-analysis
    Shin, J., I
    Kim, S. E.
    Lee, M. H.
    Kim, M. S.
    Lee, S. W.
    Park, S.
    Shin, Y. H.
    Yang, J. W.
    Song, J. M.
    Moon, S. Y.
    Kim, S. Y.
    Park, Y.
    Suh, D., I
    Yang, J. M.
    Cho, S. H.
    Jin, H. Y.
    Hong, S. H.
    Won, H-H
    Kronbichler, A.
    Koyanagi, A.
    Jacob, L.
    Hwang, J.
    Tizaoui, K.
    Lee, K. H.
    Kim, J. H.
    Yon, D. K.
    Smith, L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (10) : 3760 - 3770
  • [6] Prevalence and risk of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis
    Feier Wang
    Yubo Ma
    Shanshan Xu
    Huanhuan Liu
    Yuting Chen
    Hui Yang
    Ming Shao
    Wei Xu
    Jiangping Kong
    Liwen Chen
    Shengqian Xu
    Zongwen Shuai
    Faming Pan
    Clinical Rheumatology, 2022, 41 : 2213 - 2223
  • [7] Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis
    Akiyama, Shintaro
    Hamdeh, Shadi
    Micic, Dejan
    Sakuraba, Atsushi
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (03) : 384 - 391
  • [8] Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'
    Gremese, Elisa
    Brondani, Giovanni
    Apollonio, Luca
    Ferraccioli, Gianfranco
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (01)
  • [9] Correspondence on 'prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'
    Shi, Jiyuan
    Gao, Ya
    Zhang, Lili
    Zhao, Yang
    Xu, Jianguo
    Tian, Jinhui
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (02)